Study: NCT00882908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (R)
Description: Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (R)
Description: Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PegIFNα-2a (P)
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a (P)
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a (P)
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a (P)
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PegIFNα-2a (P)
Description: PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.